You are here

  • Home
  • Archive
  • Volume 9, Issue 3
  • Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer

 

Online download statistics by month:

Online download statistics by month: March 2021 to August 2025

AbstractFullPdf
Mar 2021515515181
Apr 2021324324107
May 202121421452
Jun 202112912941
Jul 2021959524
Aug 202113413423
Sep 202112412439
Oct 202114114152
Nov 202110911029
Dec 2021999943
Jan 2022768441
Feb 2022696940
Mar 2022495332
Apr 2022949646
May 202210310743
Jun 202212713048
Jul 202212112246
Aug 202213213223
Sep 2022889037
Oct 202211211239
Nov 20229910138
Dec 2022878734
Jan 2023838621
Feb 202311311328
Mar 202314614738
Apr 2023858537
May 2023979752
Jun 2023777731
Jul 2023616135
Aug 2023535321
Sep 2023505015
Oct 2023939327
Nov 2023515122
Dec 2023838343
Jan 2024525329
Feb 2024555539
Mar 2024707164
Apr 2024818231
May 2024565732
Jun 2024787731
Jul 2024919353
Aug 2024555420
Sep 2024646529
Oct 2024606333
Nov 2024596024
Dec 2024575830
Jan 2025677136
Feb 202510710852
Mar 2025626229
Apr 2025848437
May 2025535329
Jun 2025353615
Jul 2025110
Aug 2025100
Total522152672041